Boston, MA 08/20/2014 (wallstreetpr) – The inflation in pharmaceutical sector may not be touching eye-popping figures, but $84,000 price tag on Sovaldi drug produced by Gilead Sciences, Inc. (NASDAQ:GILD) tells a different story altogether. Most of the US lawmakers and health science experts earlier claimed that the treatment of hepatitis C will not hurt the pockets of public that much, but the price of Sovaldi proves them wrong.
Experts’ Call:
The amount that the government spends on healthcare plans is way more than the cost of Sovaldi. According to an expert, “Sovaldi is a good drug, but you will have to think from a different perspective here.” The number of patients of hepatitis C is way less than the number of people who are troubled with other diseases in US.
Reports claim that Sanofi; a healthcare company has won the approval for its pill that can cure Gaucher disease. After the approval, Sanofi can produce Cerdelga drug for adults that will not let metabolic disorder cause fatigue and fragile bones. According to reports, Gaucher is a rare disease which affects one in every 50,000-1,00,000 people. There are not more than 10000 people worldwide who have been affected by this rare disease. In US alone, this number goes up to 6,000 as per the data of National Institutes of Health. Major signs of this disease include spleen and liver enlargement, bone problems and anemia.
The Gilead Sciences, Inc. (NASDAQ:GILD) is planning to conduct a study that will compare the features of different drugs that are available in the market. After the comparison, it will also compare the cost of all the drugs and then figure out the best way to cut down the cost of this drug in the future. The main objective behind this comparative study is to make these drugs available for those people who can’t afford to spend a lot of money on drugs.
